Lundbeckfonden BioCapital
Copenhagen, DenmarkFounded 2022
Lundbeckfonden BioCapital is the venture capital arm of the Lundbeck Foundation, operating as an evergreen fund that invests in life science companies to support the translation and commercialization of groundbreaking science, primarily in Denmark.
40% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (40% of deals).
Portfolio
5
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Investment Activity
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 NMD Pharma | Series B | — | Nov 2023 |
 Cytoki Pharma | Series A | $45M | Jan 2021 |
| VVarmX BV | Series B | — | — |
| NNotify Therapeutics | Unknown | — | — |
| DDania Therapeutics | Unknown | — | — |
Top Co-Investors
INKEF Capital2 shared
Ysios Capital2 shared
+ND Capital2 shared
Roche Venture Fund1 shared
Jeito Capital1 shared
Novo Capital1 shared
Novo Holdings A/S1 shared
EQT Life Sciences1 shared
BioGeneration Ventures1 shared
InnovationQuarter1 shared
European Commission1 shared
EIFO1 shared
NanoDimension1 shared
Seventure Partners1 shared
Last updated: 19 September 2026